# OnCo record tulmimetostat (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/tulmimetostat/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "tulmimetostat" ;
  schema:name "Tulmimetostat"@en ;
  schema:alternateName "CPI-0209"@en, "DZR123"@en ;
  schema:description "Tulmimetostat is an experimental tablet that blocks the gene-silencing enzymes EZH1 and EZH2. Novartis gained it by buying MorphoSys in 2024 and is testing it in prostate cancer, lymphomas and other solid tumours."@en ;
  schema:url <https://onco.cc/drugs/tulmimetostat/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04104776>, <https://clinicaltrials.gov/search?intr=tulmimetostat> ;
  onco:status "phase-2" ;
  onco:tag "pipeline", "deal-asset" ;
  onco:modality "Oral dual EZH1/EZH2 inhibitor" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/mesothelioma/>, <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/mycosis-fungoides/>, <https://onco.cc/cancers/nsclc/> ;
  onco:targets <https://onco.cc/targets/ezh2/> ;
  onco:companies <https://onco.cc/companies/novartis/>, <https://onco.cc/companies/morphosys/> ;
  onco:trials <https://onco.cc/trials/nct04104776/>, <https://onco.cc/trials/nct07206056/>, <https://onco.cc/trials/nct07190300/>, <https://onco.cc/trials/nct05942300/>, <https://onco.cc/trials/nct05944562/>, <https://onco.cc/trials/nct05467748/> .